{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T03:08:05Z","timestamp":1772680085825,"version":"3.50.1"},"reference-count":18,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000038","name":"HHS | U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["HHSF223201610082C"],"award-info":[{"award-number":["HHSF223201610082C"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"HHS | U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["HHSF223201610082C"],"award-info":[{"award-number":["HHSF223201610082C"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,4,19]]},"abstract":"<jats:p>Neonatal sepsis is an underrecognized burden on health care systems throughout the world. Antimicrobial drug resistance (AMR) is increasingly prevalent and compromises the use of currently recommended first-line agents.<\/jats:p>","DOI":"10.1128\/aac.02181-21","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T13:00:37Z","timestamp":1647954037000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance"],"prefix":"10.1128","volume":"66","author":[{"given":"Nicola","family":"Farrington","sequence":"first","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"McEntee","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Johnson","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Unsworth","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-3413","authenticated-orcid":true,"given":"Christopher","family":"Darlow","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Jimenez-Valverde","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Hornik","sequence":"additional","affiliation":[{"name":"Division of Pediatric Critical Care Medicine, Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Division of Neonatal-Perinatal Medicine, Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Charles River Laboratories, Davis, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-4816","authenticated-orcid":true,"given":"Shampa","family":"Das","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-878X","authenticated-orcid":true,"given":"William","family":"Hope","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00050-5"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001996"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix526"},{"key":"e_1_3_2_5_2","unstructured":"Agency EM. 2006. European Community. Regulation (EC) No 1901\/2006 of the European Parliament and of the Council of medicinal products for paediatric use amended by Regulation (EC) No 1902\/2006. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32006R1902&from=EN."},{"key":"e_1_3_2_6_2","unstructured":"Pediatric study plans: content of and process for submitting initial pediatric study plans and amended initial pediatric study plans; guidance for industry. 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/pediatric-study-plans-content-and-process-submitting-initial-pediatric-study-plans-and-amended."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12025"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab025"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00285-13"},{"key":"e_1_3_2_10_2","unstructured":"Preparation of Artificial CSF. ALZET osmotic pumps. https:\/\/www.alzet.com\/guide-to-use\/preparation-of-artificial-csf\/."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/524063"},{"key":"e_1_3_2_12_2","unstructured":"Food and Drug Administration. 2019. Supplemental new drug application for Mycamine for treatment of invasive candidiasis in pediatric patients less than 4 months of age. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021506s023lbl.pdf."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05826-11"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv451"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00293-21"},{"key":"e_1_3_2_16_2","first-page":"P509","article-title":"Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution","volume":"9","author":"European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)","year":"2003","unstructured":"European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). 2003. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. Clin Microbiol Infect 9:P509\u2013P515.","journal-title":"Clin Microbiol Infect"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky128"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31825c4ba6"},{"key":"e_1_3_2_19_2","volume-title":"ADAPT 5 user\u2019s guide: pharmacokinetic\/pharmacodynamic systems analysis software.","author":"D\u2019Argenio DZ","year":"2009","unstructured":"D\u2019Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user\u2019s guide: pharmacokinetic\/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.02181-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.02181-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T13:18:00Z","timestamp":1650374280000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.02181-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,19]]}},"alternative-id":["10.1128\/aac.02181-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.02181-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]},"assertion":[{"value":"2021-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02181-21"}}